Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Sacco C, Mateo-Urdiales A, Castilla J, Martínez-Baz I, de Gier B, Hahné S, Meijerink H, Kristoffersen AB, Machado A, Soares P, Nardone A, Bacci S, Kissling E, Nunes B; VEBIS‐EHR Working Group. Monge S, et al. Among authors: meijerink h. Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292. Influenza Other Respir Viruses. 2024. PMID: 38654485 Free PMC article.
Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
Kislaya I, Sentís A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, AlKerwi A, Braeye T, Fontán-Vela M, Bacci S, Meijerink H, Castilla J, Emborg HD, Hansen CH, Schmitz S, Van Evercooren I, Valenciano M, Nardone A, Nicolay N, Monge S; VEBIS‐Lot4 working group. Kislaya I, et al. Among authors: meijerink h. Influenza Other Respir Viruses. 2023 Nov;17(11):e13195. doi: 10.1111/irv.13195. Influenza Other Respir Viruses. 2023. PMID: 38019704 Free PMC article.
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.
Fontán-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Fabiani M, Mateo-Urdiales A, AlKerwi A, Schmitz S, Castilla J, Martínez-Baz I, de Gier B, Hahné S, Meijerink H, Starrfelt J, Nunes B, Caetano C, Derrough T, Nardone A, Monge S; VEBIS-Lot4 working group; VEBIS-Lot 4 working group. Fontán-Vela M, et al. Among authors: meijerink h. Euro Surveill. 2024 Jan;29(1):2300670. doi: 10.2807/1560-7917.ES.2024.29.1.2300670. Euro Surveill. 2024. PMID: 38179626 Free PMC article.
COVID-19 Vaccine Effectiveness Among Adolescents.
Poukka E, Andersson NW, Thiesson EM, Baum U, Pihlström N, Perälä J, Kristoffersen AB, Meijerink H, Starrfelt J, Ljung R, Hviid A. Poukka E, et al. Among authors: meijerink h. Pediatrics. 2024 Jan 1;153(2):e2023062520. doi: 10.1542/peds.2023-062520. Pediatrics. 2024. PMID: 38196395
Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
Seppälä E, Dahl J, Veneti L, Rydland KM, Klüwer B, Rohringer A, Meijerink H. Seppälä E, et al. Among authors: meijerink h. Vaccine. 2024 Jan 25;42(3):620-628. doi: 10.1016/j.vaccine.2023.12.050. Epub 2023 Dec 23. Vaccine. 2024. PMID: 38142215 Free article.
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.
Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, Poukka E, Lund LC, Hansen CH, Aakjær M, Kjær J, Cohet C, Goossens M, Andersen M, Hallas J, Meijerink H, Ljung R, Hviid A. Andersson NW, et al. Among authors: meijerink h. BMJ. 2023 Jul 24;382:e074325. doi: 10.1136/bmj-2022-074325. BMJ. 2023. PMID: 37487623 Free PMC article.
49 results